CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
2 例高级别 B 细胞淋巴瘤母体 CAR-T 治疗后的新生儿结局
英文原题：Neonatal Outcomes following 2 Cases of Maternal CAR-T Therapy for High-Grade B-Cell Lymphoma.
查看英文原题
Neonatal Outcomes following 2 Cases of Maternal CAR-T Therapy for High-Grade B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
CAR-T 治疗后的妊娠似乎与不良新生儿结局无关。
中文摘要
引言：靶向CD19的CAR-T 细胞是治疗复发/难治性B细胞恶性肿瘤的一项重要进展。尽管接受CAR-T 治疗者中有相当一部分是处于生育年龄的女性，但关于既往接受CAR-T 治疗女性的妊娠和新生儿结局数据很少。这一点很重要，因为已知母体T细胞可分别在妊娠和哺乳期间通过胎盘和乳汁传播。 病例介绍：我们报告两例CAR-T 治疗后成功妊娠的病例，两名新生儿最初均接受母乳喂养。据我们所知，这是医学文献中首次对CAR-T 治疗后出生的新生儿病例作全面描述。 结论：CAR-T 治疗后妊娠似乎与新生儿不良结局无关。仍需进一步研究，以明确这一人群的结局。
展开英文摘要原文
INTRODUCTION: Chimeric antigen receptor T cells (CAR-Ts) targeting CD19 represent a significant advance in treatment for patients with relapsed/refractory B-cell malignancies. Although a significant minority of recipients are women during their reproductive years, there is a paucity of data regarding pregnancy and neonatal outcomes in women previously treated with CAR-T. This is important as maternal T cells are known to cross the placenta and into breastmilk during pregnancy and breastfeeding, respectively. CASE PRESENTATION: Here we present two successful pregnancies following CAR-T therapy where both neonates were initially breastfed. These represent the first cases of neonates born following CAR-T therapy comprehensively described in medical literature. CONCLUSION: Pregnancy following CAR-T therapy does not appear to be associated with adverse neonatal outcomes. Further work is required to delineate the outcomes in this population.
论文信息
- 作者
- O'Reilly D、Jones C、Smith A、Mackin D、Mc Donald L、Quinn J、O'Reilly M、Flinn AM
- 单位
- Department of Neonatology, The Rotunda Hospital, Dublin, Ireland.Ireland
- 文献类型
- 病例报告
- 期刊
- Neonatology2025
- 原文标识
- PubMed 39510057 · DOI 10.1159/000542016